We are proud to support @YCDjobs, a community-based organization that has provided training and job opportunities to empower San Francisco’s underserved communities for +45 years. Thank you to our colleagues Jermaine Jenkins and Robert Bacci for #makingithappen! pic.twitter.com/ZA1U1vVU0U
— Nektar Therapeutics (@NektarNews) September 8, 2020
We are excited to announce we reached an important milestone in our partnership with Vaccibody, dosing the first patient in our Phase 1/2a study arm evaluating the combination of bempeg with VB10.NEO. Read more: https://t.co/z4CYKcxmNq pic.twitter.com/3jiOo2skwE
— Nektar Therapeutics (@NektarNews) August 12, 2020
Nektar's leadership team, scientists and employees are committed to bringing transformative new #medicines to patients with debilitating diseases. Check out their progress here: https://t.co/OZp9N1CaHt pic.twitter.com/2s6F0dlyzk
— Nektar Therapeutics (@NektarNews) July 28, 2020
To help @czbiohub continue conducting research for public health challenges like #COVID19, we are donating necessary medical equipment. Read more about our COVID-19 response: https://t.co/0ixmV1mOTY pic.twitter.com/bXUAF13CWA
— Nektar Therapeutics (@NektarNews) July 24, 2020
Our Project Manager Seema Gurung wears white in support of @CancerResearch and a future #immune2cancer. Watch her personal message to all parents fighting cancer. pic.twitter.com/xeYpUYc5EX
— Nektar Therapeutics (@NektarNews) June 12, 2020
At Nektar, we are developing novel immunotherapies that harness key steps in the #cancer #immunity cycle. This #ASCO20, learn more about our investigational therapeutics. https://t.co/AlWMSedE9k $NKTR pic.twitter.com/CHsMCthrLz
— Nektar Therapeutics (@NektarNews) May 29, 2020
We are pleased to share the recent publication of findings from our Phase 1 clinical study of BEMPEG in combo with a checkpoint inhibitor for advanced solid #tumors in the journal #CancerDiscovery. Learn more: https://t.co/8qIORjnCoe @CD_AACR $NKTR pic.twitter.com/DZ7i3LPzte
— Nektar Therapeutics (@NektarNews) May 26, 2020
Our team is made up of biopharma experts who are working to bring hope to millions of patients by creating new medicines that treat serious medical needs. Learn more about the research behind $NKTR #science: https://t.co/2IpNFfrKR5 pic.twitter.com/5BSBP9SY4X
— Nektar Therapeutics (@NektarNews) April 23, 2020
Nektar is proud to be HQ'd in San Francisco. Health services agency @SFDPH is working hard to get healthcare workers the resources they need to continue caring for patients. We've donated protective equipment to support their response to #COVID19 Read more https://t.co/BbBerfyxSs pic.twitter.com/9r8ryia2y6
— Nektar Therapeutics (@NektarNews) April 16, 2020
This #WorldHealthDay we are joining @WHO's celebration of nurses who help keep the world a healthier place. Not only during this unprecedented time, but every day they are at the forefront of treatment and care. Learn more: https://t.co/ds06eef3V6 pic.twitter.com/I0hcyDPWKW
— Nektar Therapeutics (@NektarNews) April 7, 2020
During #KidneyCancerAwarenessMonth, we would like to share our gratitude for the patients and physicians who share their stories and participate in clinical trials so that research may bring new treatments with which we can fight this disease. Learn more: https://t.co/enVlrHft1J pic.twitter.com/KRreUa7bm8
— Nektar Therapeutics (@NektarNews) March 30, 2020
#Autoimmune Disease Awareness Month impacts more than 23 million Americans living with diseases like lupus, Crohn's disease and psoriasis. $NKTR is leveraging our immunology expertise to develop treatments for some of these illnesses. Learn more: https://t.co/ito30tFFxc #ADAM20 pic.twitter.com/a2PYs3J9r1
— Nektar Therapeutics (@NektarNews) March 25, 2020
Our collaboration with leading research institutions like @UCLAJCCC provide valuable insight as we work toward developing novel therapies to fight #cancer. #WorldCancerDay https://t.co/0bJQvstnYG
— Nektar Therapeutics (@NektarNews) February 4, 2020
New research published with @SpringerNature in @NatureComms from researchers @MDAndersonNews: Results show how bempeg works synergistically with multiple immune-based therapies to enhance T-cell-mediated tumor control. Click here to read: https://t.co/QR6GjWK90w pic.twitter.com/qIof9IKmzP
— Nektar Therapeutics (@NektarNews) February 3, 2020
New research published with @SpringerNature in @NatureComms from the team at Antoni Ribas’ Lab @UCLAJCCC: ACT therapy supported by bempeg increases the proliferation, homing and persistence of anti-tumor T cells in melanoma models. Click here to read: https://t.co/DXcTggM8Dj pic.twitter.com/5Eh77Vky10
— Nektar Therapeutics (@NektarNews) February 3, 2020
Dr. Nikhil Munshi @DanaFarber discusses his research on NKTR-255 in multiple myeloma. https://t.co/CvpyAXDIMt via @YouTube
— Nektar Therapeutics (@NektarNews) January 24, 2020
Nektar is proud to welcome Dr. Myriam Curet to our Board of Directors. https://t.co/pysa01I8BE pic.twitter.com/iWfUXL5Kfc
— Nektar Therapeutics (@NektarNews) December 17, 2019
Today at #PEGSEurope, our Head of Research, Loui Madakamutil, PhD, presented preclinical data for our investigational IL-15 receptor agonist and its potential benefits for #CART therapies. Read more here: https://t.co/TIkX324S0B pic.twitter.com/wW8m7HDQlB
— Nektar Therapeutics (@NektarNews) November 21, 2019
$NKTR will be at the #CICON2019 conference this week presenting data on our #immunotherapy bempeg and nivolumab in metastatic, triple-negative #breastcancer. Find details here: https://t.co/JTPnWMl7hQ #cancerresearch #oncology
— Nektar Therapeutics (@NektarNews) September 24, 2019
September is #PainAwarenessMonth. An estimated 50 million Americans are affected by chronic pain. Find out more about this year's efforts. https://t.co/zLsXxXyJi4 #LetsTalkAboutPain pic.twitter.com/TAeQKJclIp
— Nektar Therapeutics (@NektarNews) September 6, 2019
We call our approach to new therapeutic development "smart pharmacology." Discover how we define it here: https://t.co/NP3CahYrJP pic.twitter.com/PwyssluyL9
— Nektar Therapeutics (@NektarNews) July 24, 2019
Today marks the first day of #summer. Exposure to UV rays is one risk factor for skin cancer and #melanoma. Click here to find out steps you can take to stay safe in the sun. https://t.co/nMcpDgt0qO pic.twitter.com/BaclccIdLC
— Nektar Therapeutics (@NektarNews) June 21, 2019
Today, we announced the results of the first-in-human Ph 1a study evaluating NKTR-358, a first-in-class regulatory T cell stimulator in development with partner @LillyPad for the treatment of autoimmune & other chronic inflammatory conditions. Learn more: https://t.co/BaAR65fJ00 pic.twitter.com/WyiQy25ctX
— Nektar Therapeutics (@NektarNews) June 13, 2019
We’re excited to be attending #ASCO19 this year and presenting four poster boards including data from our PIVOT study, preclinical data and two of our trials in progress on melanoma and RCC. Learn more here: https://t.co/vfAPEyMVfB pic.twitter.com/eKHqUw0qn2
— Nektar Therapeutics (@NektarNews) May 31, 2019
We’re feeling inspired after attending the #SFBT gala honoring this year’s Most Influential Women in Bay Area Business winners, including our Chief Medical Officer, Mary Tagliaferri, M.D. Congratulations, Mary! https://t.co/2AySjasuMf @SFBusinessTimes pic.twitter.com/1UJImupxuc
— Nektar Therapeutics (@NektarNews) May 31, 2019
The five-year survival rate of #BladderCancer is nearly 77%, which means early detection is key. Find out more about risk factors and prevention here: https://t.co/631DFcWWkU
— Nektar Therapeutics (@NektarNews) May 30, 2019
Congratulations to our Chief Medical Officer, Mary Tagliaferri, M.D. for being included in this year’s @SFBusinessTimes Most Influential Women in Bay Area Business list. We are proud to have you on our team! https://t.co/QMIPMgRpas
— Nektar Therapeutics (@NektarNews) May 28, 2019
March is #KidneyCancer awareness month. #DYK kidney cancer is among the 10 most common cancers in both men and women and renal cell carcinoma (RCC) is the most common kind of kidney cancer in adults? Learn more: https://t.co/rr4G6RC5Qv pic.twitter.com/SEwJhMFGte
— Nektar Therapeutics (@NektarNews) March 26, 2019
This year's theme for #WorldKidneyDay is kidney health for everyone, everywhere. Find out more about efforts to bring awareness to disparities in kidney health and the importance of disease prevention and management. Learn more: https://t.co/l03vysj8E2 @worldkidneyday pic.twitter.com/VmmCdrlFnY
— Nektar Therapeutics (@NektarNews) March 14, 2019
March is Autoimmune Disease Awareness Month. #DYK researchers have identified 80-100 different autoimmune diseases? Learn more about efforts to support disease awareness: https://t.co/RNLypxyT2V #ADAM19 pic.twitter.com/d013627mkJ
— Nektar Therapeutics (@NektarNews) March 6, 2019
Our CMO, Dr. Mary Tagliaferri attended the @SFBusinessTimes “Women Who Lead in Life Sciences” forum on the state of diversity in the SF life sciences industry. Learn more about Dr. Tagliaferri and her fellow biotech leaders: https://t.co/7kh3rbZveD #SFBTwomenwholead pic.twitter.com/X0KhUHMCX4
— Nektar Therapeutics (@NektarNews) March 1, 2019
Attending @ASCO #GU19? Check out our poster presentation titled “NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.” Learn more here: https://t.co/dsPQAZ8QRh pic.twitter.com/986Hcj8O2e
— Nektar Therapeutics (@NektarNews) February 15, 2019
#DYK that bladder cancer is the 9th leading cause of cancer death in the U.S.? Despite this statistic, it has a five-year survival rate of 69.4% if diagnosed and treated early. pic.twitter.com/MFHWMjHsgA
— Nektar Therapeutics (@NektarNews) February 14, 2019
Learn more about how NKTR-214 uses a patient's own immune system to fight #cancer. pic.twitter.com/p7MQeTYDMp
— Nektar Therapeutics (@NektarNews) February 13, 2019
We are excited about our NKTR-262 in combination with NKTR-214 program. Learn more here: https://t.co/P2sajjYLjC pic.twitter.com/llblOlVdsD
— Nektar Therapeutics (@NektarNews) February 5, 2019
An estimated 18 million people were affected by cancer in 2018. On #WorldCancerDay we join together to raise awareness about the prevention, detection and treatment of cancer. Learn more: https://t.co/E1pnuaPsnz pic.twitter.com/QOiLsfALbn
— Nektar Therapeutics (@NektarNews) February 4, 2019
Learn more about #autoimmune disease and what the Nektar team is doing with NKTR-358 to bring innovative autoimmune treatments to patients in need: https://t.co/KeDIkRwka3 pic.twitter.com/EocjBva9dw
— Nektar Therapeutics (@NektarNews) December 20, 2018
Nektar's Chief R&D Officer, Dr. Steve Doberstein presents "Advanced Cytokine Engineering for Immunotherapy" @TriConference today. #TRICON https://t.co/DLv6tBuL6G
— Nektar Therapeutics (@NektarNews) March 13, 2019
Nektar is a proud sponsor of @climbtofight’s mission to support cancer research @fredhutch. Congratulations to all the members of Team Kilimanjaro for reaching the summit and raising over $1.5 million for cancer research! https://t.co/C7cEyL7fhN
— Nektar Therapeutics (@NektarNews) July 26, 2019
Today, we participated in the 7th annual Walk to Work Day in San Francisco. More than 884,000 residents, 265,000 weekday commuters and 24.6 million visitors walk in SF each year. Who else walked to work this morning? https://t.co/YbDbooXYiQ @walksf pic.twitter.com/7e2TMuB7Ld
— Nektar Therapeutics (@NektarNews) April 10, 2019
Vaccibody, Nektar begin customized cancer vaccine trial @NektarNews https://t.co/dddifRQhYz
— The Science Advisory Board (@ScienceBoard) August 13, 2020
Excited to finally have this important work published https://t.co/a2CXhMQmvi! Great collaboration with @ChilesResearch @Josh_Waka @OHSUKnight @NektarNews. Synergy between IL-2 agonist (NKTR-214/bempegaldesleukin) and local radiation therapy. #FinishCancer #immunotherapy
— William Redmond (@WWredmond4) May 26, 2020
Just published #OnlineFirst! Bempegaldesleukin plus nivolumab in patients with advanced solid tumors: Phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). @MDAndersonNews @NektarNews #ClinicalTrial #Immunotherapy https://t.co/flJGeWo5SY pic.twitter.com/lvvT1qXDHl
— Cancer Discovery (@CD_AACR) May 21, 2020
Just published in @CD_AACR: Bempegaldesleukin plus nivolumab in patients with advanced solid tumors: Phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02) @MDAndersonNews @NektarNews #ClinicalTrial #Immunotherapy https://t.co/3Q25flJDfo
— Elizabeth McKenna (@ElizSMcKenna) May 21, 2020
#Nektar Publishes Two Manuscripts On Its #Immunooncology Candidate, #Bempeg https://t.co/9M9Hc4xGMr @RTTNews @NektarNews
— Plexus Ventures (@PlexusVentures) February 4, 2020
#NektarTherapeutics is abandoning a new #opioid #painkiller after an unfavorable review by the #FDA. #chronicpain @addiction #cpp @NektarNews https://t.co/ZfmVROb4Oo
— Pain News Network (@PainNewsNetwork) January 15, 2020
FDA Panel Votes Down @NektarNews Opioid Painkiller, Asks for More Data
– by @frankvinluanhttps://t.co/qPkDkgzC5b $NKTR— Xconomy (@Xconomy) January 15, 2020
"What we have seen is a very gratifying response rate, with overall response rates ranging from 40% to 50% of patients," said Dr. Siefker-Radtke in this interview.https://t.co/5Dre5ItkBq#Gu19 #bladder #blcsm
— Targeted Oncology (@TargetedOnc) February 22, 2019
Thank you to all our generous sponsors of #BCANTT20, including @FerGeneBio @genentech @AstellasUS/@SeattleGenetics @Bristol_Myers @EMDSerono @Pfizer @JanssenOncUS @Merck @UroGenPharma @PhotocureASA QED Therapeutics @AstraZenecaUS @NektarNews pic.twitter.com/sNBleglElt
— Bladder Cancer Advocacy Network (@BladderCancerUS) August 7, 2020
We'd like to welcome Biocom's newest members: @NeuroservicesA @HrIntegral @Argo_Ops @NektarNews @CirQuestLabs, Infixion Bioscience, and Phylagen! #NewMemberMonday pic.twitter.com/mlgFcVa8yp
— Biocom (@BiocomCA) June 30, 2020
We're looking forward to @FishburnSimone @BioCentury joining #BiotechByTheLake's excellent lineup that including senior execs/scientists from @sierraoncology @CereXis, @NektarNews @genentech @pfizer @Oppenheimer @DriehausCapital @SofinnovaVC @FrazierHealth & @NorthwesternU. https://t.co/5wrWEitpMk
— CLP (@CLP_Institute) May 13, 2020
Heartfelt thanks to Nektar Therapeutics for their generous support of #TeamKili and the Climb to Fight Cancer. Private support is crucial to ending cancer as a cause of human suffering. Donations like this directly benefit researchers at @fredhutch @NektarNews @ldtimmerman pic.twitter.com/sX96KU76rk
— Climb for Fred Hutch (@climbtofight) July 25, 2019
Female #researchers have made important discoveries in the past & continue to do so today. We honor these #women, the advancements they have made & the impact they have had on the lives of people around the world. #InternationalWomensDay #STEM pic.twitter.com/l9n1rRHxlN
— aimatmelanoma (@AIMatMelanoma) March 8, 2019
#ImmunoOnc19 $NKTR Discussant S Bhatia says REVEAL 1b/II study of NKTR-214 and TLR 7/8 agonist NKTR-262 provides proof of concept in tough to treat population. pic.twitter.com/ep8oqz8Emj
— Emily (@emilykatehayes) March 1, 2019
New drug combinations could help overcome immune resistance to the anti-PD-1 blockade; @TorrejonDavis's must-read study, explains how disruptions in genes can lead to immune resistance to aPD1 therapy. cc: @apcollet
@CD_AACR @NektarNews https://t.co/yTmBeypovK https://t.co/AZmXl0y9Qh— Leo Nissola, MD (@LeoNissolaMD) May 29, 2020
Organoid Research: @NektarNews's Bempeg enhances T-cell medicated cancer therapy https://t.co/iNAVZPtfPK #organoidnews #immunonews #CancerResearch #immunology #immunotherapy
— Sciencia Consulting (@scienciaconsult) February 5, 2020
Among the many things we celebrate in February, National Cancer Prevention Month is at the top of our list. Here are a few tips for living a healthier life featuring cancer-preventative habits. https://t.co/G7ox2FjOm9
— NFCR (@NFCR) February 1, 2019
"The vast majority of breast cancers are found during daily activities like showering, applying deodorant or even scratching." – Therese Bevers, M.D. #CancerResearch #BreastCancer #EndCancer #NFCR https://t.co/hEx0r73lgx
— NFCR (@NFCR) January 11, 2019
NKTR-262 + NKTR-214 early data suggesting activity of the combination. #ImmunoOnc19 pic.twitter.com/Cu4DPPLG9r
— @gulleyj1 (@gulleyj1) March 1, 2019
Clinical Trial of NKTR-262 –well tolerated, immune activation in TME #ImmunoOnc19 pic.twitter.com/nFlQqmQSN2
— @gulleyj1 (@gulleyj1) March 1, 2019
Can you say this 3 times really fast? Bempegaldesleukin. Actually, I love this agent and stay tuned for more with cytokines and how they can bring out the best in T-cells and NK cells. #ImmunoOnc19 pic.twitter.com/NBsa6sRNZV
— @gulleyj1 (@gulleyj1) March 1, 2019
In less than 3 weeks, we are Going Purple to End #Lupus! #DYK it takes an average of 6 years to be diagnosed with lupus? That's a long time to go without getting adequate treatment! Help us reduce the time to diagnosis & pump up the purple this May! #LupusAwarenessMonth #LAM19
— Lupus Foundation of America · #WalkToEndLupusNow (@LupusOrg) April 11, 2019
It’s #WomensHistoryMonth so this #WCW is dedicated to all of the women researchers determined to beat lupus! 25+ brilliant women currently hold significant grants from the LRA & each one is making a difference. We thank them for their support & dedication to the lupus community! pic.twitter.com/Fb6P5TE1y5
— Lupus Research (@LupusResearch) March 20, 2019
Delighted to welcome Dr Willem Overwijk, Nektar Therapeutics to IO Combinations 360 taking place on June 20-21 in Philadelphia. He will be speaking about Harnessing the IL-2 Pathway in Combination Immunotherapies https://t.co/Oochux0EIS #IOCombos360 @NektarNews #immunotherapy pic.twitter.com/tfiXNmNQOT
— The Conference Forum (@ConferenceForum) June 15, 2019
Going from big pharma to small biotech we hear Dr Wei Lin, @NektarNews discuss his transition from going from established oncology giant Roche/Genentech to Nektar Therapeutics, a clinical-stage biotech with a pipeline of promising immune-oncology candidates #CMOBoston pic.twitter.com/bk2K8SUvfY
— The Conference Forum (@ConferenceForum) April 5, 2019
Starting on Track 1A, Immuno-Oncology, we have Dr Beth Trehu, Dr Christina Coughlin, Dr IIdiko Csiki , Dr Wei Lin and Dr Ian Walters discussing how you approach a partnership as a small biotech when large pharma dominates the space #CMOBoston @JounceTx @NektarNews @IntensityInc pic.twitter.com/xPrsShHlPi
— The Conference Forum (@ConferenceForum) April 4, 2019
Nektar's polymer chemistry technology was used to create NKTR-214, a CD122-biased cytokine that targets the IL-2 pathway – excited to hear the clinical results with Dr Jonathan Zalevsky @NektarNews #io360nyc pic.twitter.com/oSvZa58Enu
— The Conference Forum (@ConferenceForum) February 6, 2019